revacept
Jump to navigation
Jump to search
Contraindications
- addition to currently recommended antithrombotic therapy in the setting of percutaneous coronary intervention in patients with stable ischemic heart disease does not reduce the incidence of myocardi
Mechanism of action
More general terms
References
- ↑ Schupke S, Hein-Rothweiler R, Mayer K et al ISAR-PLASTER-Trial Investigators. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial. Thromb Haemost. 2019 Sep;119(9):1539-1545. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31226721
- ↑ Mayer K, Hein-Rothweiler R, Schupke S et al Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart DiseaseThe Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiol. Published online March 31, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33787834 https://jamanetwork.com/journals/jamacardiology/fullarticle/2777812